{"id":34154,"date":"2023-11-10T17:00:33","date_gmt":"2023-11-10T16:00:33","guid":{"rendered":"https:\/\/www.abcsg.org\/?p=34154"},"modified":"2023-11-11T06:02:52","modified_gmt":"2023-11-11T05:02:52","slug":"latest-big-newsletter-reports-on-the-abcsg-52-athene-study","status":"publish","type":"post","link":"https:\/\/www.abcsg.org\/en\/latest-big-newsletter-reports-on-the-abcsg-52-athene-study\/","title":{"rendered":"Latest BIG newsletter reports on the ABCSG 52 \/ ATHENE study"},"content":{"rendered":"<p>Successful recruitment during COVID-19 pandemic and very promising trial results!<!--more--><\/p>\n<p>The ABCSG 52 \/ ATHENE study is investigating the efficacy and safety of a neoadjuvant immunochemotherapy regimen consisting of atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer patients in regards to pathologic complete response (pCR).<\/p>\n<p>The impressive pCR rate of the study was presented for the first time by Assoc. Prof. Dr. Gabriel Rinnerthaler at the &#8220;ESMO 2023 Breast&#8221; in May in Berlin in the &#8220;Best Abstracts Session 2&#8221;.<\/p>\n<p>Furthermore, at the San Antonio Breast Cancer Conference 2023, a secondary analysis regarding pCR according to early metabolic remission in an interim FDG-PET scan and to tumour infiltrating lymphocytes will be presented.<\/p>\n<p><strong><a href=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2023\/11\/BIG_Issue-No.-19.2023_G.Rinnerthaler.pdf\" target=\"_blank\" target=\"_blank\" rel=\"noopener\">Download Article <\/a><\/strong><\/p>\n<p><a href=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2023\/11\/big-research-in-focus-19.pdf\" target=\"_blank\" target=\"_blank\" rel=\"noopener\"><strong>Download BIG Newsletter No. 19 \/ November 2023<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Successful recruitment during COVID-19 pandemic and very promising trial results!<\/p>\n","protected":false},"author":1,"featured_media":34155,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[505],"tags":[573,574],"class_list":["post-34154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-big-en","tag-abcsg-52-en"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-25 16:34:58","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/34154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=34154"}],"version-history":[{"count":2,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/34154\/revisions"}],"predecessor-version":[{"id":34160,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/34154\/revisions\/34160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media\/34155"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=34154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/categories?post=34154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=34154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}